Barrington Research Weighs in on OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Investment analysts at Barrington Research boosted their FY2028 EPS estimates for shares of OPKO Health in a research note issued to investors on Friday, November 8th. Barrington Research analyst M. Petusky now expects that the biotechnology company will earn $0.00 per share for the year, up from their previous estimate of ($0.01). Barrington Research has a "Outperform" rating and a $2.25 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.29) per share.

OPK has been the subject of a number of other research reports. HC Wainwright reiterated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reissued an "overweight" rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. Finally, StockNews.com raised shares of OPKO Health to a "sell" rating in a report on Saturday, July 27th.

OPKO Health Price Performance

Shares of NASDAQ OPK traded up $0.05 during midday trading on Monday, reaching $1.57. The stock had a trading volume of 5,047,202 shares, compared to its average volume of 6,990,167. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -8.26 and a beta of 1.65. OPKO Health has a 12-month low of $0.85 and a 12-month high of $1.75. The stock has a 50-day moving average of $1.51 and a 200-day moving average of $1.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in OPKO Health by 23.7% in the 1st quarter. BNP Paribas Financial Markets now owns 336,315 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 64,443 shares during the last quarter. Headlands Technologies LLC bought a new stake in OPKO Health during the 1st quarter valued at about $47,000. Lazard Asset Management LLC purchased a new stake in OPKO Health in the 1st quarter valued at about $258,000. Price T Rowe Associates Inc. MD grew its stake in OPKO Health by 4.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company's stock worth $536,000 after acquiring an additional 17,671 shares in the last quarter. Finally, AWM Investment Company Inc. increased its position in shares of OPKO Health by 18.2% during the first quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company's stock worth $1,560,000 after acquiring an additional 200,000 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at OPKO Health

In related news, major shareholder Opko Health, Inc. sold 39,824 shares of the firm's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $33.08, for a total value of $1,317,377.92. Following the completion of the transaction, the insider now directly owns 2,746,972 shares of the company's stock, valued at approximately $90,869,833.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Phillip Md Et Al Frost bought 280,183 shares of the company's stock in a transaction dated Friday, November 8th. The stock was purchased at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the acquisition, the chief executive officer now owns 211,512,405 shares in the company, valued at $317,268,607.50. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Opko Health, Inc. sold 39,824 shares of the business's stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $33.08, for a total value of $1,317,377.92. Following the transaction, the insider now directly owns 2,746,972 shares in the company, valued at approximately $90,869,833.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 47.26% of the stock is owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.